

<b>Test Name</b>	<b>Genes</b>
ASPiRA GenetiX BRCA1, BRCA2	<i>BRCA1, BRCA2</i>
ASPiRA GenetiX BRCA1, BRCA2 reflex to Targeted Breast and Ovarian 24	<i>BRCA1, BRCA2 reflexed if pathogenic or likely pathogenic variants are not detected</i>
ASPiRA GenetiX BRCA1, BRCA2 reflex to Comprehensive Breast and Ovarian	<i>BRCA1, BRCA2 reflexed if pathogenic or likely pathogenic variants are not detected</i>
<sup>34</sup> ASPiRA GenetiX Targeted Breast and Ovarian 24	<i>ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER, EPCAM, MLH1, MSH2, (mono/biallelic), MSH6, MRE11A, NBN, NFI, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53</i>
ASPiRA GenetiX Comprehensive Breast, Ovarian and Endometrial 34	<i>ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, FANCC, FANCM, MLH1, MRE11(A), MSH2, (mono/biallelic), MSH6, MUTYH, NBN, NF1, NTHL1 (mono/biallelic), PALB2, POLE, POLD1, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL (WRN), SDHB, SDHD, SMARCA4, STK11, TP53, XRCC2</i>

Inversion of MSH2 exons 1-7 (“Boland” inversion) is only assessed for Targeted or Comprehensive Panel testing (Endometrial Cancer risk only). This testing is available upon request.